Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesLong-Term Debt IssuancesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables RefundsShares OutstandingShort-Term Debt repayments
Ratios

BioNexus Gene Lab (BGLC) Accumulated Depreciation & Amortization (2019 - 2025)

Historic Accumulated Depreciation & Amortization for BioNexus Gene Lab (BGLC) over the last 7 years, with Q3 2025 value amounting to $971148.0.

  • BioNexus Gene Lab's Accumulated Depreciation & Amortization rose 2507.52% to $971148.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $971148.0, marking a year-over-year increase of 2507.52%. This contributed to the annual value of $983153.0 for FY2024, which is 1109.02% up from last year.
  • As of Q3 2025, BioNexus Gene Lab's Accumulated Depreciation & Amortization stood at $971148.0, which was up 2507.52% from $943747.0 recorded in Q2 2025.
  • In the past 5 years, BioNexus Gene Lab's Accumulated Depreciation & Amortization ranged from a high of $994915.0 in Q1 2025 and a low of -$4739.0 during Q4 2022
  • Its 5-year average for Accumulated Depreciation & Amortization is $751652.7, with a median of $805273.0 in 2022.
  • As far as peak fluctuations go, BioNexus Gene Lab's Accumulated Depreciation & Amortization tumbled by 10082.56% in 2022, and later soared by 1877491.03% in 2023.
  • Quarter analysis of 5 years shows BioNexus Gene Lab's Accumulated Depreciation & Amortization stood at $574014.0 in 2021, then crashed by 100.83% to -$4739.0 in 2022, then skyrocketed by 18774.91% to $885004.0 in 2023, then rose by 11.09% to $983153.0 in 2024, then fell by 1.22% to $971148.0 in 2025.
  • Its Accumulated Depreciation & Amortization was $971148.0 in Q3 2025, compared to $943747.0 in Q2 2025 and $994915.0 in Q1 2025.